- UroToday Home
- Urologic Oncology
The Latest Bladder Cancer Research
Recent Abstracts
-
Health Care Utilization and Costs Associated With Blue-Light vs White-Light Cystoscopy: A Real-World Bladder Cancer Population.Bladder CancerAugust 10, 2026
-
Prognostic significance of non-muscle-invasive late recurrence after intravesical bacillus Calmette-Guérin therapy in bladder cancer: a multicenter, retrospective real-world study (the Japan Urological Oncology Group).Bladder CancerAugust 10, 2026
-
Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice.Bladder CancerAugust 7, 2026
-
Integrating clinically actionable biomarkers into bladder cancer care - recommendations from the International Bladder Cancer Group.Bladder CancerAugust 7, 2026
-
En-bloc Resection of Bladder Tumor Versus Conventional Transurethral Resection of Bladder Tumor: Long-term Oncological Outcomes from a Single-center Prospective Trial.Bladder CancerAugust 6, 2026
-
Oncological outcomes of extended versus standard pelvic lymph node dissection in radical cystectomy: An updated systematic review and meta-analysis.Bladder CancerAugust 6, 2026
-
Comparison of Sex-Specific Treatment Outcomes in Clinical Trials and Subsequent Real-World Data on Systemic Therapies for Urothelial Carcinoma: A Systematic Review.Bladder CancerAugust 6, 2026
-
Association between time from diagnosis to radical cystectomy and oncologic outcomes in muscle-invasive urothelial carcinoma of the bladder.Bladder CancerAugust 5, 2026
-
ERBB2 Copy Number Alterations and Protein Expression in Bladder Cancer Treated by Cystectomy.Bladder CancerAugust 5, 2026
-
Paclitaxel and carboplatin after disease progression on immune checkpoint inhibitor for patients with metastatic urothelial carcinoma.Bladder CancerAugust 4, 2026
Beyond the Abstracts
-
A Machine-Learning Approach to Predict Additional Treatment after Bacillus Calmette-Guérin Induction in Non-Muscle-Invasive Bladder Cancer - Beyond the AbstractBladder CancerJuly 30, 2026
-
Histological Subtypes and Divergent Differentiation of Urothelial Carcinoma: Histology, Genomics, and Management Implications - Beyond the AbstractBladder CancerJuly 27, 2026
-
Pathological Assessment of Morcellated Tissue after ERBT: Insights from a Two-Round Delphi Survey - Beyond the AbstractBladder CancerJuly 17, 2026
-
Time to Treatment Initiation and Survival in Patients With Muscle-Invasive Bladder Cancer (MIBC) - Beyond the AbstractBladder CancerJuly 14, 2026
-
Factors Influencing Adherence to Intravesical Instillation Therapies for Non-Muscle-Invasive Bladder Cancer: A Scoping Review Protocol - Beyond the AbstractBladder CancerJuly 14, 2026
-
AI-MIRACLE: Artificial Intelligence and MultIpaRAmetric MRI Predict CLinical OutcomEs to Neoadjuvant Immunotherapy in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy - Beyond the AbstractBladder CancerJuly 14, 2026
-
Diagnosis, Evaluation, and Management of Patients with Non-Muscle Invasive Bladder Cancer - Beyond the AbstractBladder CancerJuly 9, 2026
-
Outcomes of Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A Real-World Experience - Beyond the AbstractBladder CancerJuly 8, 2026
-
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes from the JAVELIN Bladder 100 Trial in Patients with High Body Mass Index or Diabetes Mellitus - Beyond the AbstractBladder CancerJuly 2, 2026
-
International Survey of Thromboprophylaxis Practices During Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer - Beyond the AbstractBladder CancerJuly 1, 2026